An appeal letter for Zepbound answers one thing: the reason on the denial. Everything else in it is evidence for that answer. The drug’s maker publishes a guide to writing one, and federal rules for employer and individual plans set what the plan must do with it. The deadlines themselves are in Zepbound denied by insurance; this page is about the letter.
Who writes it
Lilly describes the letter of medical necessity as the prescriber’s explanation of their rationale and clinical decision-making, and says many plans require one for an appeal[1]. It notes that some plans have their own coverage authorization form that must be used instead[1].
You can also appeal yourself. HealthCare.gov says to complete the insurer’s forms or write with your name, claim number and insurance ID number, and to add anything you want considered, such as a letter from the doctor[3]. A plan may set procedures for authorizing someone to act for you[2]. In an urgent-care claim, a health care professional who knows your condition must be allowed to act as your authorized representative[2]. For Medicare, Lilly notes, a prescriber must meet specific requirements to act as the patient’s representative[1].
Start from the denial, not from a template
The denial notice must give the specific reason, the plan provisions it rests on, and any extra information needed to perfect the claim, with why it is needed[2]. If the plan relied on an internal rule or guideline, the notice must include it or say you can have a copy free on request[2]. A medical necessity denial must come with an explanation of the clinical judgment, or an offer of one free on request[2].
That list is the brief for the letter. Lilly’s sample for a new start opens by naming the denial reason and says to copy it verbatim from the plan’s letter[1]. A letter that answers the plan’s own criterion, point by point, gives the reviewer nothing to look for elsewhere.
What goes in it
| Part of the letter | What the guide asks for |
|---|---|
| Who and which case | Patient's full name, date of birth, plan ID number, and the case number if the plan has already decided |
| Who is writing | The prescriber's National Provider Identifier and specialty |
| The diagnosis | Patient history with clinical and progress notes, and the diagnosis with its specific ICD code |
| How severe it is | The patient's BMI, plus any reduced-calorie diet, physical activity or lifestyle program tried |
| Related conditions | Relevant comorbid conditions, with obstructive sleep apnea given as the example |
| What was tried before | Earlier medicines or therapies, how long each ran and why each stopped, with procedure or J-codes where useful |
| The support | Chart notes and, where relevant, the Zepbound Prescribing Information or peer-reviewed literature |
Both of Lilly’s samples then set out past treatments in a table of drug, start and stop dates and reason for stopping, and close with the prescriber’s view of the likely course without Zepbound[1]. The letter is signed by the prescriber, and the samples leave a line for the patient too[1].
Tie the diagnosis to one of the two labeled uses
Lilly’s sample says plainly that the patient must have a diagnosis consistent with Zepbound’s indications[1]. The label has two: long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition; and moderate to severe obstructive sleep apnea in adults with obesity[4].
The trials behind the weight indication enrolled adults with a BMI of 30 or more, or 27 to under 30 with a condition such as high blood pressure, abnormal cholesterol, sleep apnea or heart disease[4]. The sleep apnea trials enrolled adults with an apnea-hypopnea index of 15 or more and a BMI of 30 or more[4]. Lilly’s second sample leaves a place for the ICD code of each case: obesity, overweight with a weight-related condition, or sleep apnea with obesity[1].
Which use the letter claims can matter under public programs too, where weight-loss use and sleep apnea use of tirzepatide are handled differently. See does Medicare cover Zepbound and does Medicaid cover Zepbound.
A new start and a restart read differently
Lilly gives two samples. The first is for a patient not yet on Zepbound and asks the plan to reassess its denial[1]. The second is for a patient who was treated and then had treatment interrupted, and argues that continuing is medically appropriate and necessary[1].
Both samples ask for the same records, including weight and BMI history and the trial or failure of other treatments[1]. For someone who has already taken Zepbound, that history includes the time on it.
What the plan must do with it
A group health plan must give you at least 180 days after the denial to appeal[2]. You may submit written comments, documents and records, and the review must take all of them into account whether or not they were part of the first decision[2]. When the denial rests on medical judgment, including whether a drug is medically necessary, the reviewer must consult a health care professional with the right training and experience[2].
Lilly’s own guide is candid about the limits: it does not guarantee success in getting a plan to pay, and it tells prescribers to check each plan’s requirements[1].
Keep the paper trail
Keep the denial, the Explanation of Benefits, a copy of the appeal and everything sent with it[3]. Note every call with the date, time, name and title of the person you spoke to[3]. Send copies and keep the originals[3].
If you pay while the appeal runs, what the maker charges without coverage is in Zepbound price, and what the card does with and without coverage is in Zepbound savings card. Whether your plan lists Zepbound at all is covered in is Zepbound covered by insurance.